| Cheng, Xiangdong |
NCT04135781: Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer |
|
|
| Recruiting | 3 | 616 | RoW | nab paclitaxel, albumin bound paclitaxel, Tegafur, S-1, Oxaliplatin, Capecitabine | Zhejiang Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Stomach Cancer | 10/24 | 10/24 | | |
NCT05009953: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer |
|
|
| Terminated | 2 | 17 | RoW | Irinotecan Liposome Injection, SG001, Fluorouracil, Leucovorin | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma | 01/23 | 01/23 | | |
NCT05864105: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 35 | RoW | PM8002, FOLFOX regimen | Biotheus Inc. | Hepatocellular Carcinoma | 06/26 | 06/26 | | |
NCT06586294: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 294 | RoW | Drug: AK129 Drug：oxaliplatin Drug：capecitabine, Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
NCT05911984: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 27 | RoW | 9MW3811 Injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumor | 03/24 | 03/24 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
BAT-8007-001-CR, NCT05879627: To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | BAT8007 for injection, Recombinant all human anti Nectin-4 monoclonal antibody for injection Exatecan conjugate | Bio-Thera Solutions, Zhejiang Tumor Hospital | Advanced Solid Tumors | 12/24 | 07/25 | | |
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies |
|
|
| Terminated | 1 | 13 | RoW | HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Malignancies | 02/23 | 05/23 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT05836948: The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 174 | RoW | SHR-9839 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/26 | 06/26 | | |
NCT05794841: Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract |
|
|
| Recruiting | N/A | 20000 | RoW | Tongue coating sample collection and multi-omics analysis | Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Liaoning Tumor Hospital & Institute, RenJi Hospital, Fujian Cancer Hospital, Sun Yat-sen University, The Second Affiliated Hospital of Harbin Medical University, Sichuan Cancer Hospital and Research Institute, Zhejiang Provincial Tongde Hospital, Yuhang District Hospital of Traditional Chinese Medicine, The First People's Hospital of Yuhang District, The First Affiliated Hospital of Anhui University of Chinese Medicine, BGI-Shenzhen, Shangyu People's Hospital, Xianju People's Hospital, Shanghai Zhongshan Hospital | Malignant Tumors of Digestive Tract | 03/24 | 03/25 | | |
| Yang, Haiyan |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
| Yu, Aijun |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
